About Us

Home > About Histogen > Management

Gail K. Naughton, Ph.D., CEO, Chairman of the Board

Gail K. NaughtonDr. Gail Naughton founded Histogen, Inc. in 2007, and currently serves as CEO and Chairman of the Board for the Company. She has spent more than 25 years extensively researching the tissue engineering process, holds more than 95 U.S. and foreign patents, and has been extensively published in the field.gnaughton@histogeninc.com

David Nassif, President and CFO

David NassifDavid W. Nassif, J.D. was appointed President and CFO in May 2011. Previously, he was a principal at Strategic Consulting Services, providing high-level management consulting to life sciences companies, including Histogen. He served as the Executive Vice President, Chief Financial Officer, Secretary and Treasurer of Zogenix, Inc. from May 2007 to March 2010 after consulting for Zogenix from October 2006 to May 2007. From May 2006 to October 2006, as well as earlier from 2001 to 2002, Previously, Mr. Nassif served as a principal at Strategic Consulting Services providing capital raising, mergers and acquisitions, licensing and investor relations services to various public and private life science and technology companies.

Mark Baumgartner, Director of Engineering

Mark BaumgartnerMr. Baumgartner joined the company in 2007 with more than 20 years experience in product and process development for regulated biologic products. During 2006 and 2007 Mr. Baumgartner worked as a consultant to the biomedical and biopharmaceutical sectors on several projects for product development and process engineering. Mr. Baumgartner worked as Director of Process Development for Smith-Nephew Wound Management LLC, producing biological medical device products from 2002 to 2006. mbaumgartner@histogeninc.com

Dr. Mark A. Hubka, Director of Clinical Affairs

Dr. Mark A. HubkaDr. Hubka brings more than 25 years of clinical experience from the fields of orthopedics and sports medicine to Histogen. His experience in managed care includes his time as State Director of the largest designated provider network (DPN) in California, focused on worker's compensation. mhubka@histogeninc.com

Eileen Naughton Brandt, Director of Corporate Communications

Eileen Naughton BrandtEileen brings more than 5 years of experience in communications and public relations to Histogen. Prior to joining Histogen in 2007, she held positions with Moore Media Relations, Inc., a firm working with high-technology companies throughout the U.S. on various PR projects, with a focus on media relations. Previously, Eileen held positions at San Diego State University's Entrepreneurial Management Center, beginning as a Student Assistant at the San Diego State University and later serving as Program Coordinator. ebrandt@histogeninc.com

Emmett Pinney B.S., M.S., Director of Oncology & Special Projects

Emmett PinneyIn addition to degrees in Microbiology and Bioengineering, Emmett brings 35 years of laboratory experience to Histogen, including 10 years in Research & Development for Advanced Tissue Sciences where he was instrumental in developing some of their most successful products as well as supervising the internship program. Emmett holds 6 domestic and international patents, and has authored 25 peer reviewed articles. He was also the Co-Founder and CSO of a small profitable biotech company, Intella, L.L.C. epinney@histogeninc.com

Michael P. Zimber, Ph.D., Director of Applied Research

Michael P. ZimberDr. Michael Zimber brings to Histogen over 15 years of diverse experience in the biotechnology and pharmaceutical industry with a multi-disciplinary background in early phase discovery, preclinical development and translational phases of therapeutic development. He began his scientific career studying developmental biology conducting research on tissue pattern formation and amphibian limb regeneration. mzimber@histogeninc.com

Histogen Inc. is a regenerative medicine company based on the commercialization of products manufactured by newborn human cells.
  • Broad range of markets, which are underserved and expected to grow
  • Rich product portfolio
  • Solutions without the use of embryonic stem cells or animal products
© Histogen Inc., CA 92121